3D-QSAR and Molecular Docking Studies on Derivatives of MK-0457, GSK1070916 and SNS-314 as Inhibitors against Aurora B Kinase
Open Access
- 2 November 2010
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 11 (11) , 4326-4347
Abstract
Development of anticancer drugs targeting Aurora B, an important member of the serine/threonine kinases family, has been extensively focused on in recent years. In this work, by applying an integrated computational method, including comparative molecular field analysis (CoMFA), comparative molecular similarity indices analysis (CoMSIA), homology modeling and molecular docking, we investigated the structural determinants of Aurora B inhibitors based on three different series of derivatives of 108 molecules. The resultant optimum 3D-QSAR models exhibited (q2 = 0.605, r2pred = 0.826), (q2 = 0.52, r2pred = 0.798) and (q2 = 0.582, r2pred = 0.971) for MK-0457, GSK1070916 and SNS-314 classes, respectively, and the 3D contour maps generated from these models were analyzed individually. The contour map analysis for the MK-0457 model revealed the relative importance of steric and electrostatic effects for Aurora B inhibition, whereas, the electronegative groups with hydrogen bond donating capacity showed a great impact on the inhibitory activity for the derivatives of GSK1070916. Additionally, the predictive model of the SNS-314 class revealed the great importance of hydrophobic favorable contour, since hydrophobic favorable substituents added to this region bind to a deep and narrow hydrophobic pocket composed of residues that are hydrophobic in nature and thus enhanced the inhibitory activity. Moreover, based on the docking study, a further comparison of the binding modes was accomplished to identify a set of critical residues that play a key role in stabilizing the drug-target interactions. Overall, the high level of consistency between the 3D contour maps and the topographical features of binding sites led to our identification of several key structural requirements for more potency inhibitors. Taken together, the results will serve as a basis for future drug development of inhibitors against Aurora B kinase for various tumors.Keywords
This publication has 35 references indexed in Scilit:
- Discovery of GSK1070916, a Potent and Selective Inhibitor of Aurora B/C KinaseJournal of Medicinal Chemistry, 2010
- 2-Aminobenzimidazoles as potent Aurora kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- The discovery of the potent aurora inhibitor MK-0457 (VX-680)Bioorganic & Medicinal Chemistry Letters, 2009
- Discovery and Development of Aurora Kinase Inhibitors as Anticancer AgentsJournal of Medicinal Chemistry, 2009
- Discovery of a potent and selective Aurora kinase inhibitorBioorganic & Medicinal Chemistry Letters, 2008
- Aurora A and B Overexpression and Centrosome Amplification in Early Estrogen-Induced Tumor Foci in the Syrian Hamster Kidney: Implications for Chromosomal Instability, Aneuploidy, and NeoplasiaCancer Research, 2007
- Aurora-kinase inhibitors as anticancer agentsNature Reviews Cancer, 2004
- VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivoNature Medicine, 2004
- Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochoresJournal of Cell Biology, 2003
- The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore–microtubule attachment and in maintaining the spindle assembly checkpointJournal of Cell Biology, 2003